Free Lesson Preview
This is just the beginning
The full CRC track covers 8 courses from study start-up to close-out — the skills sponsors actually look for.
View enrollment optionsAlready enrolled? Sign in
Free GCP training
Professional tracks
Clinical Research Coordinator
Full course · The CRC Role: Foundations and Career Path
Free Lesson Preview
The full CRC track covers 8 courses from study start-up to close-out — the skills sponsors actually look for.
View enrollment optionsAlready enrolled? Sign in
Understand the paradigm shift from retrospective quality control to prospective quality management introduced in ICH E6(R3), and what this means for how CRCs think about their daily work.
I want to tell you about a pattern I have observed at clinical research sites for over 25 years. A coordinator finishes a monitoring visit. The monitor has reviewed 30 participant charts, verified source documents against the EDC, checked regulatory binders, and examined consent forms. The coordinator asks the question that coordinators always ask at the end: "How did it go?" The monitor says: "Looks good. Just a few minor findings."
And the coordinator exhales. Good visit. No problems.
But here is what I want you to notice about that interaction. The entire quality conversation happened after the fact. The work was done weeks or months ago. The monitor arrived, looked backward through that completed work, and rendered a verdict. The coordinator's definition of quality was, in essence: did someone check my work and find it acceptable?
This is retrospective quality control. And for decades, it was the dominant model in clinical research. Quality meant inspection. Quality meant someone else--a monitor, an auditor, a sponsor representative--looking at finished work and deciding whether it passed. The coordinator's job was to do the work. Someone else's job was to check it.
ICH E6(R3), finalized on 6 January 2025, says this is not good enough. Not because monitors are unnecessary--they are not going anywhere. But because a model built entirely on after-the-fact inspection is structurally inadequate for protecting participants and ensuring data reliability. The new guideline introduces something fundamentally different: the expectation that quality is designed into clinical trial processes before the work begins, not verified only after the work is complete.
This distinction--between finding problems and preventing them--is, in my view, the single most consequential shift that E6(R3) introduces for the daily work of clinical research coordinators.
What you will learn4 objectives
By the end of this lesson, you will be able to:
Progress saves itself — finish reading and this lesson completes